163 related articles for article (PubMed ID: 9204460)
21. Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells.
Yam P; Jensen M; Akkina R; Anderson J; Villacres MC; Wu J; Zaia JA; Yee JK
Mol Ther; 2006 Aug; 14(2):236-44. PubMed ID: 16647299
[TBL] [Abstract][Full Text] [Related]
22. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes.
Ramezani A; Ma XZ; Ameli M; Arora A; Joshi S
Front Biosci; 2006 Sep; 11():2940-8. PubMed ID: 16720366
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection.
BouHamdan M; Duan LX; Pomerantz RJ; Strayer DS
Gene Ther; 1999 Apr; 6(4):660-6. PubMed ID: 10476226
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
25. Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors.
Costello E; Munoz M; Buetti E; Meylan PR; Diggelmann H; Thali M
Gene Ther; 2000 Apr; 7(7):596-604. PubMed ID: 10819575
[TBL] [Abstract][Full Text] [Related]
26. Interference between effector RNAs expressed from conventional dual-function anti-HIV retroviral vectors can be circumvented using dual-effector-cassette retroviral vectors.
Peng H; Callison D; Li P; Burrell CJ
Hum Gene Ther; 1999 Feb; 10(3):449-62. PubMed ID: 10048397
[TBL] [Abstract][Full Text] [Related]
27. Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics.
Garg M; Asthana A; Agashe HB; Agrawal GP; Jain NK
J Pharm Pharmacol; 2006 May; 58(5):605-16. PubMed ID: 16640829
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
29. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy.
Duan L; Zhu M; Ozaki I; Zhang H; Wei DL; Pomerantz RJ
Gene Ther; 1997 Jun; 4(6):533-43. PubMed ID: 9231069
[TBL] [Abstract][Full Text] [Related]
30. [Comparative evaluation of Hebei HIV-1 p24 kit for the detection of human immunodeficiency virus].
Yang YS; Wang RT; Zhang XG; Zhang HZ; Wang HF; Li ZL; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):8-10. PubMed ID: 17429521
[TBL] [Abstract][Full Text] [Related]
31. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.
Li MJ; Kim J; Li S; Zaia J; Yee JK; Anderson J; Akkina R; Rossi JJ
Mol Ther; 2005 Nov; 12(5):900-9. PubMed ID: 16115802
[TBL] [Abstract][Full Text] [Related]
32. Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy.
Hörster A; Teichmann B; Hormes R; Grimm D; Kleinschmidt J; Sczakiel G
Gene Ther; 1999 Jul; 6(7):1231-8. PubMed ID: 10455431
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy clinical trials for HIV.
Statham S; Morgan RA
Curr Opin Mol Ther; 1999 Aug; 1(4):430-6. PubMed ID: 11713756
[TBL] [Abstract][Full Text] [Related]
34. Increased gene transfer into human CD34+ progenitor cells using retroviral vectors produced by a canine packaging cell line.
Bauer G; Sauter S; Ibanez C; Rice CR; Valdez P; Jolly D; Kohn DB
Biol Blood Marrow Transplant; 1998; 4(3):119-27. PubMed ID: 9923409
[TBL] [Abstract][Full Text] [Related]
35. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
36. StpC-based gene therapy targeting latent reservoirs of HIV-1.
Turner LS; Tsygankov AY; Henderson EE
Antiviral Res; 2006 Dec; 72(3):233-41. PubMed ID: 16891001
[TBL] [Abstract][Full Text] [Related]
37. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
Chang LJ; Liu X; He J
Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line.
Michienzi A; Conti L; Varano B; Prislei S; Gessani S; Bozzoni I
Hum Gene Ther; 1998 Mar; 9(5):621-8. PubMed ID: 9551610
[TBL] [Abstract][Full Text] [Related]
39. Anti-HIV diterpenes from Coleus forskohlii.
Bodiwala HS; Sabde S; Mitra D; Bhutani KK; Singh IP
Nat Prod Commun; 2009 Sep; 4(9):1173-5. PubMed ID: 19831022
[TBL] [Abstract][Full Text] [Related]
40. Alpha-momorcharin inhibits HIV-1 replication in acutely but not chronically infected T-lymphocytes.
Zheng YT; Ben KL; Jin SW
Zhongguo Yao Li Xue Bao; 1999 Mar; 20(3):239-43. PubMed ID: 10452099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
